476 related articles for article (PubMed ID: 33758645)
1. Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Wang CR; Tsai HW
World J Diabetes; 2021 Mar; 12(3):238-260. PubMed ID: 33758645
[TBL] [Abstract][Full Text] [Related]
2. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
3. [THE EFFECT OF BIOLOGIC THERAPY ON THE LIPID PROFILE OF RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) AND ANKYLOSING SPONDYLITIS (AS) PATIENTS].
Hassan S; Feld J; Cohen S; Zisman D
Harefuah; 2017 Jul; 156(7):446-450. PubMed ID: 28786273
[TBL] [Abstract][Full Text] [Related]
4. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Voulgari PV
Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
[TBL] [Abstract][Full Text] [Related]
5. Role and Function of A
Ravani A; Vincenzi F; Bortoluzzi A; Padovan M; Pasquini S; Gessi S; Merighi S; Borea PA; Govoni M; Varani K
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338619
[TBL] [Abstract][Full Text] [Related]
6. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Campas-Moya C
Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
[TBL] [Abstract][Full Text] [Related]
7. Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients.
Chen HH; Chen DY; Lin CC; Chen YM; Lai KL; Lin CH
Ther Clin Risk Manag; 2017; 13():583-592. PubMed ID: 28496328
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
9. Anti cytokine therapy in chronic inflammatory arthritis.
Thompson C; Davies R; Choy E
Cytokine; 2016 Oct; 86():92-99. PubMed ID: 27497159
[TBL] [Abstract][Full Text] [Related]
10. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
11. Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review.
Dal Bello G; Gisondi P; Idolazzi L; Girolomoni G
Rheumatol Ther; 2020 Jun; 7(2):271-285. PubMed ID: 32306243
[TBL] [Abstract][Full Text] [Related]
12. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
13. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
[TBL] [Abstract][Full Text] [Related]
14. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.
Partsch G; Steiner G; Leeb BF; Dunky A; Bröll H; Smolen JS
J Rheumatol; 1997 Mar; 24(3):518-23. PubMed ID: 9058659
[TBL] [Abstract][Full Text] [Related]
15. [Insulin resistance and metabolic syndrome - a different image of disorders in rheumatoid arthritis and ankylosing spondylitis].
Dąbrowski P; Majdan M
Wiad Lek; 2015; 68(3):235-41. PubMed ID: 26753206
[TBL] [Abstract][Full Text] [Related]
16. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
17. IL-23 and Th17 Disease in Inflammatory Arthritis.
Yago T; Nanke Y; Kawamoto M; Kobashigawa T; Yamanaka H; Kotake S
J Clin Med; 2017 Aug; 6(9):. PubMed ID: 28850053
[TBL] [Abstract][Full Text] [Related]
18. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
19. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
20. Distinguishing rheumatoid arthritis from psoriatic arthritis.
Merola JF; Espinoza LR; Fleischmann R
RMD Open; 2018; 4(2):e000656. PubMed ID: 30167326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
